Clinical trial
A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
NCT05276063 is registered in ClinicalTrials.gov with Sling Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
- Lead sponsor
- Sling Therapeutics, Inc.
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- July 1, 2022
- Completion date
- September 26, 2025
- Enrollment
- 90 (actual)
- Sites
- 30
Conditions
As the registry lists them; a condition with its own page is linked.
endocrine system diseases, exophthalmos, eye diseases, graves ophthalmopathy, graves orbitopathy, hashimoto, igf1r, orbital diseases, proptosis, thyroid associated ophthalmopathy, thyroid diseases, thyroid eye disease